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Abstract
Objective: We have used receiver operating characteristic (ROC) analysis to determine the diagnostic
performance of several serum parameters, in order to evaluate their potential usefulness in
establishing the diagnosis of polycystic ovary syndrome (PCOS) in epidemiological studies.
Design: Prospective study.
Methods: One hundred and fourteen women reporting spontaneously for blood donation were
included in the study. Menopausal and oral contraceptive-treated women were excluded. Serum
samples were obtained at the moment of donation, independently of fasting, time of day or day of
menstrual cycle. Measurements included total testosterone, sex hormone-binding globulin (SHBG),
dehydroepiandrosterone sulfate (DHEAS), LH, FSH and estradiol. The free testosterone (FT)
concentration and the free androgen index (FAI) were calculated from testosterone and SHBG levels.
ROC curves were calculated for all these serum determinations.
Results: Eight patients were diagnosed with PCOS, according to the presence of oligomenorrhea,
hirsutism, acne and/or hyperandrogenemia, and exclusion of non-classic congenital adrenal
hyperplasia, hypothyroidism and hyperprolactinemia. Of the parameters studied SHBG, FAI, FT and
DHEAS were considered adequate measures for the diagnosis of PCOS. For example, serum SHBG
levels showed an area under the ROC curve of 0.875^(S.E.w)0.045 (95% confidence interval 0.800–
0.929). A SHBG decision threshold ,37 nmol/l had a sensitivity of 87.5%, a specificity of 86.8%, a
positive likelihood ratio of 6.63, and a negative likelihood ratio of 0.14, for the diagnosis of PCOS.
Conclusions: Our present results strongly suggest that decreased SHBG levels, and increased FAI, free
testosterone concentration and DHEAS concentrations, are highly effective as single analytical
procedures in epidemiological studies for the detection of PCOS in women of reproductive age.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the more
prevalent endocrine disorders in women, affecting 4–
7% of women of reproductive age (1–3).
The widely accepted research criteria for the
diagnosis of PCOS are derived from the conference
sponsored in 1990 by the National Institute of Child
Health and Human Development (NICHD) (4). Most of
the participants in this conference agreed that PCOS
diagnosis requires, in order of importance: (i) clinical
and/or biochemical hyperandrogenism, (ii) oligo-
ovulation, and (iii) exclusion of other etiologies such
as non-classic congenital adrenal hyperplasia, hyper-
prolactinemia or androgen-secreting tumors (4). Detec-
tion of polycystic ovaries by ultrasound was not
considered essential for the diagnosis of PCOS (4),
and later studies have confirmed the limited value of
sonographic parameters for the prediction of the
hormonal abnormalities characteristic of PCOS (5).
The broad application of these criteria has permitted
significant advances in our knowledge of PCOS, such as
the precise evaluation of its prevalence (1, 2), or the
recognition of PCOS as a familial syndrome (6, 7).
However, because no indications were given in the
NICHD conference on how to define the individual
criteria (4), this ambiguity may be responsible in part
for the frequent discrepancies found in the literature
regarding the prevalence and pathophysiology of
PCOS.
In a clinical setting, the use of NICHD criteria is easy.
Ovulation can be monitored using basal body tempera-
ture charts or serum progesterone measurement on
days 22–24 of the menstrual cycle, and sampling for
serum androgens can be controlled for the day of the
menstrual cycle or the hour of the day.
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On the contrary, in population-based studies invol-
ving large number of subjects, the NICHD criteria for
the diagnosis of PCOS are difficult to apply, a problem
that is especially evident in epidemiological and familial
studies. The accuracy of the NICHD criteria may
decrease if several observers are involved in the
evaluation of hirsutism and clinical hyperandrogenism,
and the methods needed for the precise evaluation of
ovulatory function are not usually applicable for large
transversal studies.
In this context, appropriate use of non-subjective
variables, such as some serum variables likely to be
related to PCOS, may facilitate and improve the
diagnosis of this condition. However, the performance
of serum hormone determinations for PCOS detection
in that setting has not been studied, and most familial
and epidemiological studies rely only on serum
testosterone levels for diagnosing biochemical hyper-
androgenism and PCOS (3, 8, 9).
Receiver operating characteristic (ROC) curves are
used in the evaluation of diagnostic test performance
(10). ROC curves are a graphical representation of the
relationship between the sensitivity and the specificity
of a diagnostic test over all possible diagnostic cut-off
values (10). In addition to the evaluation of test
performance, ROC curves are used to choose the cut-off
values for diagnostic tests, either to obtain maximum
sensitivity, maximum specificity, or a balance of both.
ROC analysis has been used to evaluate the
diagnostic performance of serum hormone determina-
tions for PCOS detection in a clinical setting, namely,
the discrimination of PCOS patients from other
hyperandrogenic patients and from healthy controls,
under controlled sampling conditions (11, 12).
On the contrary, the diagnostic performance of
serum determinations for PCOS detection in epidemio-
logical studies has not been established. For this reason,
in the present study we have performed ROC analysis,
considering NICHD criteria as the ‘gold-standard’ for
the diagnosis of PCOS, of the basal serum concentra-
tions of several hormones and related parameters
usually measured in these patients, in order to evaluate
their potential usefulness as single diagnostic tests for
screening for this disorder in epidemiological studies.
Materials and methods
Subjects, protocol and assays
One hundred and fifty-four consecutive women were
recruited prospectively, after giving informed consent,
to participate in a study to evaluate the prevalence of
PCOS, and hirsutism, in Spain (1). These women were
blood donors reporting spontaneously to the Blood
Bank of the Hospital Ramo´n y Cajal. For the present
study, women in whom no serum samples were
obtained, and those women taking oral contraceptives,
were excluded, the latter because of the profound
impact of oral contraceptive treatment in steroidogenic
and gonadotropic hormone profiles.
One hundred and fourteen women were finally
included in the present study. The presence of hirsut-
ism, acne and menstrual dysfunction were recorded as
described in detail elsewhere (1). Serum samples were
obtained at the moment of blood donation, and
therefore these samples were not controlled for fasting,
time of day or day of menstrual cycle.
Serum was assayed for total testosterone, sex hor-
mone-binding globulin (SHBG), dehydroepiandro-
sterone sulfate (DHEAS), luteinizing hormone (LH),
follicle-stimulating hormone (FSH) and estradiol (E2).
The free testosterone (FT) concentration and the free
androgen index (FAI) were calculated from testosterone
and SHBG concentrations, as previously described (1,
13). In women presenting with clinical and/or biochem-
ical evidence of hyperandrogenism and menstrual
dysfunction, serum prolactin and 17-hydroxyprogester-
one measurements excluded hyperprolactinemia and
non-classic congenital adrenal hyperplasia (1). Serum
concentrations of the above variables were assayed as
described elsewhere (1).
Women were diagnosed with PCOS when presenting
with menstrual dysfunction, clinical and/or biochemical
hyperandrogenism, and exclusion of other etiologies.
Menstrual dysfunction was considered when the women
had oligomenorrhea, defined by more than six cycles per
year with a length of more than 36 days (14), and/or
when the patient had not had any menstrual bleeding
for three consecutive months, during the last year.
Clinical hyperandrogenism was defined by the presence
of hirsutism, represented by a hirsutism score of 8 or
more (15), by persistence of acne during the third decade
of life or later, or by the presence of androgenic alopecia.
Hyperandrogenemia was defined by a circulating
testosterone, FT, DHEAS and/or FAI higher than the
95th percentile of the women studied here who had no
clinical evidence of hyperandrogenism, or menstrual
disturbances, and who were not taking hormonal
medication nor had had previous oophorectomy or
hysterectomy. Normal serum concentrations of
prolactin (,24 mg/l), thyrotropin (0.5–4.5 mIU/l) and
17-hydroxyprogesterone (,6.05 nmol/l) excluded
hyperprolactinemia, thyroid dysfunction and non-classic
21-hydroxylase deficiency in all the women who
achieved the other criteria for the diagnosis of PCOS.
Informed consent was obtained from every patient
and control. The study was approved by the Institu-
tional Review Board of the Hospital Ramo´n y Cajal, and
was conducted according to principles expressed in the
Declaration of Helsinki.
ROC analysis
For ROC analysis, patients presenting with PCOS were
considered affected, and the remaining women were
considered non-affected.
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ROC curves are constructed by plotting the sensitiv-
ity (true-positive fraction) on the ordinate as a function
of the complement of specificity (false-positive fraction),
for all the possible cut-off values of the diagnostic test
(10). Therefore, the more deviated towards the left
upper corner the curve is, the higher the sensitivity and
the specificity the diagnostic test has for all possible cut-
off values or, namely, the higher the adequacy of the
diagnostic test for disease detection (16).
As opposed to accuracy, sensitivity (or 1–(false-
negative fraction)) and specificity (or 1–(false-positive
fraction)) are not dependent on the prevalence of the
disease in the sample. Thus, ROC curve analysis
provides a description of disease detectability, which is
independent from both disease prevalence and decision
threshold effects (16).
The area under the ROC curve (AURC), which can be
calculated using the trapezoidal rule, characterizes
ROC curves. The AURC represents the probability of
correctly distinguishing between affected and non-
affected subjects (17). Therefore, the perfect diagnostic
test, not having false-positive or false-negative results,
would have an AURC of 1 and, on the contrary, tests
with AURCs #0.5 would not discriminate between
affected and non-affected individuals.
The Wilcoxon statistic, W, is used to test the null
hypothesis that the diagnostic test cannot be used to
discriminate between affected and non-affected subjects
(i.e. the probability equals 0.5), and is also used to
predict the statistical properties of the AURC (17). For
ROC analysis, the most important property is the
standard error (S.E.w), allowing the calculation of the
95% confidence interval (CI) (AURC^1.96 S.E.w) (17).
ROC curve analysis, and the statistical significance of
the differences in the AURC of the ROC curves of the
different serum determinations, were calculated using
ROCKIT 0.9b software (Dr Charles E Metz, Department
of Radiology, University of Chicago, Chicago, IL, USA).
The unpaired t-test or the Mann–Whitney U–Wilcoxon
W test was used to compare PCOS patients and non-
affected subjects, as appropriate. P , 0:05 was con-
sidered statistically significant.
Results
Eight of the 114 women included in the studied were
diagnosed with PCOS. For ROC curve analysis, the eight
patients with PCOS were considered as affected, and the
remaining 106 women were considered as non-
affected. In the latter group, there were two women
presenting with hirsutism, and another 12 women had
acne, but their menstrual cycles were regular, and
therefore they were not considered to have PCOS.
The clinical and biochemical characteristics of both
groups are shown in Table 1. PCOS patients were
younger than non-affected individuals, and tended to
have higher hirsutism scores. On the contrary, no
statistically significant differences were observed
among the groups in body mass index, waist-to-hip
ratio, age at menarche and number of previous
pregnancies and abortions. PCOS patients presented
with increased FT, FAI and DHEAS levels, and
decreased SHBG concentrations, as compared with
non-affected subjects. Testosterone levels also tended to
be higher in PCOS patients than in non-affected
individuals, whereas no differences were observed in
LH, FSH and E2.
The AURCs for the different hormone serum mea-
surements are shown in Table 2. The highest AURC
was that of serum SHBG, followed by the two
measurements of free testosterone (FAI and FT) and
DHEAS levels. We did not find statistically significant
Table 1 Clinical and hormonal variables in PCOS subjects and non-affected subjects. PCOS was
defined according to NICHD endocrine criteria (4). Result are means^S.D. Serum samples were not
controlled for fasting, time of day or day of menstrual cycle.
PCOS
n  8
Non-affected subjects
n  106 P-value*
Age (years) 25.0^5.4 34.5^9.4 ,0.01
Body mass index (kg/m2) 25.5^4.2 24.2^3.1 0.280
Waist-to-hip ratio 0.80^0.07 0.80^0.06 0.952
Age at menarche (years) 13.1^1.5 12.5^1.5 0.398
Number of pregnancies 0.8^0.9 1.4^1.4 0.223
Number of abortions 0.1^0.4 0.3^0.8 0.541
Hirsutism score 6.8^7.8 2.3^2.3 0.096
SHBG (nmol/l) 32.3^17.7 68.4^38.6 ,0.001
FAI 6.5^5.1 2.4^2.4 ,0.005
DHEAS (mmol/l) 11.6^4.2 6.7^3.8 ,0.005
Calculated FT (pmol/l) 33.8^22.0 16.2^14.0 ,0.005
Total testosterone (nmol/l) 1.7^0.9 1.3^0.8 0.065
E2 (pmol/l) 217^148 331^256 0.204
LH (IU/l) 8.1^5.2 10.2^11.0 0.803
FSH (IU/l) 7.4^2.9 11.8^18.2 0.816
*The unpaired t-test or the Mann–Whitney U–Wilcoxon W test was used to compare PCOS patients and non-affected
subjects, as appropriate.
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differences between these AURCs, with the exception of
a higher AURCs for the FAI as compared with FT z 
23:599; P , 0:001). However, our study did not have
statistical power to detect such small differences (i.e. at
least 557 subjects are needed to detect differences
between AURCs of 0.875 and 0.825 with a 90%
power).
Serum testosterone, E2, LH and FSH levels had small
AURCs, which were statistically lower as compared
with those of SHBG, FAI, FT and DHEAS (data not
shown), possibly reflecting the variability of serum
sampling with respect to the day of the menstrual cycle.
The ROC curves of SHBG, FAI, FT and DHEAS are
represented in Fig. 1, and the suggested decision
thresholds for the detection of PCOS using these
measurements are summarized in Table 3. The best
combination of sensitivity (0.875) and specificity
(0.868) was that of SHBG, using a decision threshold
of ,37 nmol/l. In fact, only one of the eight patients
with PCOS had SHBG values $37 nmol/l whereas 14
of the 106 non-affected women had SHBG levels
,37 nmol/l.
Discussion
For years, research into PCOS has been burdened by
the different criteria used for its definition. The
adoption of the endocrine criteria introduced after the
NICHD conference in 1990 (4) has permitted signifi-
cant advances in our knowledge of this disorder in the
last decade. Among other milestones, the broad
adoption of these criteria has allowed the recognition
of PCOS as an extremely frequent disorder, that occurs
in 4–7% of women of reproductive age (1, 2),
presenting with familial association (8), and associated
with significant reproductive, metabolic and cardio-
vascular morbidity (18).
However, the NICHD criteria for the diagnosis of
PCOS may be difficult to apply, especially in situations
involving large numbers of women, such as in familial
and epidemiological studies. On the one hand, there is
no consensus on the particular definition of these
criteria. Clinical and/or biochemical evidence for
hyperandrogenism may be interpreted differently;
some authors require hyperandrogenemia for PCOS
diagnosis (3, 9), whereas the presence of hirsutism or
acne is enough for others (1, 2). Also, the precise
diagnosis of oligo-ovulation is difficult, requiring
techniques (basal body temperature charts, luteal
phase serum progesterone levels) that are not usually
available for epidemiological studies. For these studies,
most authors use oligomenorrhea as indicative of oligo-
ovulation (1, 2, 9), but again there is no consensus
regarding the length of the menstrual cycle or the
number of menstrual cycles per year required for the
definition of oligomenorrhea.
Figure 1 ROC curves for the detection of PCOS in epidemiological
studies using SHBG levels, FAI, DHEAS concentrations and
calculated FT, measured in basal serum samples not controlled for
fasting, time of day or day of menstrual cycle.
Table 3 Decision thresholds for the detection of PCOS as defined by NICHD endocrine criteria (4).
Measurement
Decision
threshold Sensitivity Specificity
Positive likelihood
ratio
Negative likelihood
ratio
SHBG ,37 nmol/l 0.875 0.868 6.63 0.14
Calculated FT .23 pmol/l 0.625 0.849 4.14 0.44
FAI .3.67 0.750 0.858 5.30 0.29
DHEAS .11.6 mmol/l 0.625 0.915 7.36 0.41
Table 2 AURC of serum hormone concentrations for
PCOS detection in women. PCOS was defined
according to NICHD endocrine criteria (4). Serum
samples were not controlled for fasting, time of day or
day of menstrual cycle.
Hormone AURC^S.E. (95% CI)
SHBG 0.875^0.045 (0.800–0.929)
FAI 0.867^0.083 (0.790–0.923)
DHEAS 0.832^0.091 (0.750–0.895)
Calculated FT 0.830^0.091 (0.748–0.894)
Total testosterone 0.690^0.107 (0.592–0.774)
E2 0.635^0.093 (0.540–0.723)
LH 0.527^0.108 (0.431–0.621)
FSH 0.525^0.108 (0.492–0.619)
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Our present results suggest that serum determina-
tions might be enough for the screening of PCOS in
epidemiological studies. This approach has the advan-
tage of not relying on qualitative or semi-quantitative
parameters for PCOS diagnosis, such as hirsutism
scores, presence or absence of acne, or number and
length of menstrual cycles, which are difficult to
standardize. Moreover, this approach may avoid clinical
evaluation of the subjects, which usually needs special
training of the research team.
Accordingly, we have evaluated the adequacy of
several serum parameters to discriminate between
women with or without PCOS in an unselected
population-based sample using ROC analysis, applying
NICHD criteria as the ‘gold-standard’ for PCOS definition.
Not surprisingly, ROC curve analysis suggests that FAI,
FT and DHEAS measurements are adequate for this
purpose, as hyperandrogenemia is one of the criteria for
the diagnosis of PCOS. However, serum SHBG concen-
tration appears to be equally useful, and especially
adequate to detect women with PCOS. The AURC for
SHBG was 0.875 (0.800–0.929), namely, serum SHBG
has a 0.875 probability of correctly discriminating
between women with PCOS and those without this
syndrome. This figure is comparable to those of widely
accepted diagnostic tests, such as serum thyrotropin
IRMA assays for the diagnosis of hyperthyroidism (19).
We chose a serum SHBG level ,37 nmol/l as
decision threshold for the diagnosis of PCOS, because
of its high sensitivity and specificity, and its elevated
positive likelihood ratio. Although the AURC for SHBG
was not statistically higher than the AURC of the other
serum hormone levels, the balance of sensitivity and
specificity at the suggested SHBG ,37 nmol/l decision
threshold was the best of all the parameters tested,
suggesting that SHBG might be the ideal parameter for
PCOS detection in epidemiological studies.
The performance of serum SHBG for the diagnosis of
PCOS is in agreement with its pivotal role in the
pathophysiology of this syndrome. SHBG synthesis and
secretion are down-regulated by androgens and,
specifically, by increased portal insulin levels (20).
Insulin resistance, resulting in compensatory hyper-
insulinism and reduced SHBG levels, is central to the
development of PCOS (21).
In our series, reduced SHBG levels were specifically
associated with PCOS, and did not result from the
known association of PCOS with obesity (22), because
the body mass index and the waist-to-hip ratio (and
index of central adiposity, and of insulin resistance
(23)) were virtually identical in PCOS patients and non-
affected individuals.
Furthermore, serum SHBG, FT and DHEAS concen-
trations and the FAI allowed PCOS detection in our study
independently of sampling conditions, including fasting
(critical for evaluation of insulin sensitivity), time of day
(which may affect serum adrenal steroid levels), or day of
the menstrual cycle (critical for serum gonadotropins
and E2), and this is a major advantage in situations in
which sampling conditions are difficult to control, such
as in epidemiological or familial research studies.
Conversely, the absence of control for sampling
conditions in our present study probably explains the
poor performance of serum gonadotropins and E2,
certainly affected by the wide variations of these
hormones during the menstrual cycle, and is possibly
related to the relative inadequacy of testosterone for
PCOS detection. On the contrary, those androgens that
do not change markedly during the menstrual cycle,
such as DHEAS, or the indexes of FT calculated from
SHBG, were also useful for PCOS detection.
ROC analysis has several advantages for the evalua-
tion of the adequacy of diagnostic tests, including that
it is not dependent on the prevalence of the disorder to
be detected, and does not depend on the decision
threshold employed (16). However, ROC analysis has
limitations, mainly related to the definition of the
independent criteria by which the diagnosis is made,
bias selection of subjects with complete sets of the
diagnostic tests to be compared, and appropriateness of
the sample to the clinical scenario in which the
diagnostic test is going to be used (10).
In our study the independent criteria for PCOS
definition were those of the NICHD conference of 1990,
and all the subjects had the same serum parameters
measured, thus avoiding selection bias. However, our
present results should only be applied to epidemiologi-
cal or population-based studies, in which only a small
fraction of the population is expected to have PCOS.
Because of these considerations, it is important to
emphasize that our present results cannot be extrap-
olated to clinical practice, in which serum hormone
determinations are used to differentiate PCOS from
other forms of hyperandrogenism, and sampling con-
ditions are usually controlled.
For this purpose, two recent studies have used
logistic regression analysis and ROC analysis to
determine the performance of several serum measure-
ments in detecting PCOS in a clinical setting. Turhan
et al. (11) evaluated prospectively the performance of
serum LH, FSH, testosterone, FT, SHBG and insulin
concentration in a group of 32 consecutive women
with PCOS, defined by NICHD criteria and ultrasono-
graphy, and 25 healthy controls. The best fit was
obtained by including LH/FSH ratio, insulin and
testosterone concentrations in the model, but only
LH/FSH ratio and insulin retained significance in the
forced entry method in logistic regression analysis
(11). Serum SHBG was not included in the model
(11). The authors then performed ROC analysis of
LH/FSH ratio and insulin levels, obtaining AURCs of
0:823^0:032 and 0:813^0:037 respectively (11),
values that are comparable to those we have found
in our present study. Only by combining LH/FSH
ratio and insulin levels did they obtain an AURC of
0:929^0:063 (11).
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In the second study, Koskinen et al. (12) showed that
an estimate of the probability of PCOS, derived from the
levels of the variables retained in the logistic regression
model (serum LH, FSH and androstenedione concentra-
tions), had the highest clinical utility for discriminating
PCOS patients and controls in a clinical setting. LH, LH/
FSH ratio, testosterone and androstenedione serum
determinations had an AURC above 0.900 (12). Surpris-
ingly, serum SHBG levels had a low AURC, and were not
useful for PCOS detection in their series (12). However,
this study had significant differences from our present
study and from that of Turhan et al. (11): women with
PCOS were recruited retrospectively – a potential source
of bias – and the diagnosis of PCOS was based on the
presence of oligomenorrhea and sonographic polycystic
ovaries, instead of relying on NICHD criteria (12).
In conclusion, performance of serum SHBG, FT, FAI
and DHEAS measurements for the detection of PCOS in
epidemiological studies is very high even when
sampling conditions are not controlled. If our pre-
liminary results are confirmed by future studies in
larger population-based studies, the screening of PCOS
may be based on the determination of serum para-
meters, instead of relying in inaccurate clinical criteria.
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